Main Article Content
Taking polypharmacy for glycemic control is continuously increasing among diabetic patients during treatment. The purpose of this study was to investigate the association between polypharmacy and glycemic control among diabetic patients. This was hospital-based prospective study. In total, 20,809 diabetic patients were diagnosed by physicians. Of these, 8,322 diabetic patients were enrolled in this study from January to December 2015. Multiple logistic regression analysis was performed to investigate the association between polypharmacy and glycemic control. Subjects who took 5 or more medicines were less likely to control their HbA1C level (Odds ratio [OR] = 0.78; 95% confidence interval [CI], 0.71 - 0.87), and subjects who took 2 or more diabetic medicines were 2 times more likely to control their HbA1C level (OR = 2.19; 95% CI, 1.99 - 2.41). In conclusion, total polypharmacy was associated with a reduction of HbA1C level. Furthermore, diabetic polypharmacy was also associated with controlling of HbA1C level. The study findings suggest that patients on polypharmacy should be intensively monitored for uncontrollable HbA1C level. In addition, comprehensive holistic care and rationale drug use should be concerned.
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
2. Hu, F.B. Globalization of diabetes: the role of diet, lifestyle, and genes. Diabetes care. 2011; 34: 1249-1257.
3. Aekplakorn W, Porapakkham Y, Taneepanichskul H, Pakjareon H, Satearnnopakao W, Thaikla K. The 4th report of Thailand national health surveys by physical examination 2008-2009. The graphico systems Co.Ltd., Nonthaburi, Thailand. 2009; 311.
4. Ministry of Public Health, Bureau of Non-Communicable diseases. The number and morbidity rate per 100,000 populations of patient with diabetes mellitus (E10-E14) in Thailand from 2007 to 2013 [Internet]. 2015 [cited 2015 Oct 12]. Available from: http://www.thaincd.com/information-statistic/non-communicable-disease-data.php
5. Tatsanavivat P, Thavornpitak Y, Pongchaiyakul C. Comparative effectiveness of three national healthcare schemes in Thailand: in-hospital medical expenses for diabetes and hypertension in 2010. J Med Assoc Thai. 95(7): S254-S261.
6. Chatterjee S, Riewpaiboon A, Piyauthakit P, Riewpaiboon W, Boupaijit K, Panpuwong N, Archavanuntagul V. Cost of diabetes and its complications in Thailand: a complete picture of economic burden. Health Soc Care Community 2011;19: 289-298.
7. Kuney N. Literature Review: The current situation and care model of non-communicable diseases. Art Qualified; Bangkok 2014; 56.
8. America Diabetes Association. Standards of Medical Care in Diabetes-2015 Abridged for Primary Care Providers. Clin Diabetes 2015; 33:97-111.
9. Moen J, Antonov K, Larsson, CA, Lindblad U, Nilsson JL, Rastam L, Ring L. Factors associated with multiple medication use in different age groups. Ann Pharmacother 2009; 43: 1978-1985.
10. Yen P.K. Vitamins and disease prevention. Geriatr Nurs 2003; 24: 316-317.
11. Stoehr G., Lu SY, Lavery L, Bilt JR, Saxton JA, Chang CC, Ganguli M. Factors associated with adherence to medication regimens in older primary care patients: the steel valley seniors survey. Am J Geriatr pharmacother 2008; 6:255-263.
12. UKPDS. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837-53.
13. Rollason V, Vogt N. Reduction of polypharmacy in the elderly: a systematic review of the role of the pharmacist. Drugs Aging 2003; 20: 817-832.
14. Grant RW, Pirraglia PA, Meigs JB, Singer DE. Trends in complexity of diabetes care in the United States from 1991 to 2000. Archives of internal medicine 2004; 164: 1134-1139.
15. Longo D., Fauci AS, Kasper DL, Hauser SL, Jameson JL, Loscalzo J. Harrison’s principles of internal medicine. 18th ed. The McGraw-Hill Companies. New York. 2012
16. Lau DT, Kasper JD, Potter DE, Lyles A. Potentially inappropriate medication prescriptions among elderly nursing home residents: their scope and associated resident and facility characteristics. Health Serv Res 2004; 39: 1257-1276.
17. Fialova D, Topinkova E, Gambassi G, Finne-Soveri H, Jonsson PV, Carpenter I, Schroll M, Onder G, Sorbye LW, Wagner C, Reissigova J, Bernabei R, Ad HOC Project Research Group. Potentially inappropriate medication use among elderly home care patients in Europe. JAMA 2005; 293: 1348-1358.
18. Corsonello A, Pedone C, Corica F, Mussi C, Carbonin P,Incalzi RA. Concealed renal insufficiency and adverse drug reactions in elderly hospitalized patients. Arch Intern Med 2005; 165: 790-795.
19. Jyrkka J, Enlund H, Korhonen MJ, Sulkava R, Hartikainen S. Poly-pharmacy status as an indicator of mortality in an elderly population. Drugs Aging 2009; 26: 1039-1048.28.
20. Richardson K, Ananou A, Lafortune L, Brayne C, Matthews FE. Variation over time in the association between polypharmacy and mortality in the older population. Drugs Aging 2011; 28: 547-560.
21. Cashion WT. A Polypharmacy Model and the Association of Polypharmacy with All-Cause Mortality and Incident Cognitive Impairment in the REGARDS Cohort. [Ph.D. Dissertation]. Department of Epide-miology, Rollins School of Public Health, Laney Graduate School, Emory University, Atlanta, Georgia, United States 2015; 136.
22. Leiss W, Mean M, Limacher A, Righini M, Jaeger K, Beer HJ, Osterwalder J, Frauchiger B, Matter CM, Kucher N, Scherrer AA, Cornuz J, Banyai M, Lammle B, Husmann M, Egloff M, Aschwanden M, Rodondi N, Aujesky D. Polypharmacy is associated with an increased risk of bleeding in elderly patients with venous thromboembolism. J Gen Intern Med 2015; 30: 17-24.
23. Lai SW, Lin CH, Liao KF, Su LT, Sung FC, Lin CC. Association between polypharmacy and dementia in older people: a population-based case-control study in Taiwan. Geriatr Gerontol Int 2012; 12: 491-498.
24. Gallacher KI, Batty GD, McLean G, Mercer SW, Guthrie B, CR May, Langhorne P, Mair FS. Stroke, multimorbidity and polypharmacy in a nationally representative sample of 1,424,378 patients in Scotland: implications for treatment burden. BMC Med 2014; 12: 1-20.
25. Ruwald MH, Hansen ML, Lamberts M, Hansen CM, Nume AK, Vinther M, Kober L, Pedersen CT, Hansen J, Gislason GH. Comparison of incidence, predictors, and the impact of co-morbidity and polypharmacy on the risk of recurrent syncope in patients <85 versus >/=85 years of age. Am J Cardiol 2013; 112: 1610-1615.
26. Huang ES, Karter AJ, Danielson KK, Warton EM, Ahmed AT. The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: the diabetes and aging study. J Gen Intern Med 2010; 25: 141-146.
27. Kojima T, Akishita M, Nakamura T, Nomura K, Ogawa S, Iijima K, Eto M, Ouchi Y. Polypharmacy as a risk for fall occurrence in geriatric outpatients. Geriatr Gerontol Int 2012; 12: 425-430.
28. Bennett A, Gnjidic D, Gillett M, Carroll P, Matthews S, Johnell K, Hilmer S. Prevalence and impact of fall-risk-increasing drugs, polypharmacy, and drug-drug interactions in robust versus frail hospitalised falls patients: a prospective cohort study. Drugs Aging 2014; 31: 225-232.
29. Willey CJ, Andrade SE, Cohen J, Fuller JC, Gurwitz JH. Polypharmacy with oral antidiabetic agents: an indicator of poor glycemic control. Am J Manag Care 2006; 12: 435-440.
30. Rakleng S, Woradet S, Chaimay B. Prevalence of using polypharmacy in diabetic treatment among diabetic patients type II in Phatthalung province. Journal of Health Science 2017; 26: 1073-1081 (In Thai).
31. Grylls WK, McKenzie JE, Horwath CC, Mann JI. Lifestyle factors associated with glycaemic control and body mass index in older adults with diabetes. Eur J Clin Nutr 2003; 57: 1386-1393.
32. Halter JB, Ouslander JG, Tinetti ME, Studenski S, High KP, Asthana S. Hazzard's geriatric medicine and gerontology. 6th edition. The McGraw-Hill Companies. New York, United States 2009; 1664.
33. Ministry of Public Health. Health Data Center: HDC [Internet]. 2015 [cited 2016Jan 11] Available from: http://hdcservice.moph.go.th/ hdc/main
34. Medical Research Network of the Consortium of Thai Medical Schools. An Assessment on Quality of Care among Patients Diagnosed with Type 2 Diabetes and Hypertension Visiting Hospitals of Ministry of Public Health and Bangkok Metropolitan Administration in Thailand [Internet]. 2014 [cited 2016 March 11] Available from: http://dmht.thaimedresnet.org
35. Noale M, Veronese N, Perin PC, Pilotto A, Tiengo A, Crepaldi G, Maggi, S. Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta diabetol 2016; 53:323-330.
36. Manakitjongkol W. Use of The Medication Regimen Complexity Index (MRCI) to Assess Diabetic Outpatient Adherence at Saraburi Hospital Bangkok. [M.Sc. Thesis]. Department of Pharmacy, Faculty of Phamaceutical Science, Chulalongkorn University, Bangkok, Thailand 2006; 97.
37. Huri HZ, Wee HF. Drug related problems in type 2 diabetes patients with hypertension: a cross-sectional retrospective study. BMC Endocrine Disorders 2013; 13:2.
38. Juarez DT, Sentell T, Tokumaru S, Goo T, Davis JW, Mau, M.M. Factors associated with poor glycemic control or wide glycemic variability among diabetes patients in Hawaii, 2006-2009. Prev Chronic Dis 2012; 9: 1-10.
39. Hartz A, Kent S, James P, Xu Y, Kelly M, Daly J. Factors that influence improvement for patients with poorly controlled type 2 diabetes. Diabetes Res Clin Practe 2006; 74:227-232.
40. Benoit SR, Fleming R, Tsimikas AP, Ji M. Predictors of glycemic control among patients with Type 2 diabetes: a longitudinal study. BMC Public Health 2005; 5: 1-9.
41. Fox KM, Pharmd RA, Bolinder B, Chen J, Kumar S. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: A series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006; 28: 388-395.